Stephanie Nolen

A once-robust H.I.V. treatment and prevention system, credited with saving hundreds of thousands of lives, has begun to crumble.

As Canada weighs the future of medically assisted death, one woman fears the law will change too late for her.

A chronic lack of investment in development of better tests has left clinicians blind and allows deadly viruses to spread unchecked.

The vaccine development process and coordination between health organizations have improved since a devastating 2014-2016 outbreak.

Trials are beginning on several drugs that have shown promise in preliminary studies against the virus that is causing the current outbreak.

A Powerful H.I.V. Drug Lands in Zambia. But Will It Reach Those Who Need It?

A generic version of a breakthrough cystic fibrosis drug, manufactured in Bangladesh for a fraction of the American price, may give some families around the world an unlikely lifeline.

Companies in Africa and India will make generic versions of the pill that could cost as little as $5 per person per year. But access to the drug and other new products in much of Latin America remains uncertain.

The amount is still far below what the U.S. spent previously on humanitarian and health aid, but resumes the flow of money for key efforts to fight malnutrition and disease.

The malaria-carrying mosquito is resistant to all insecticides. Scientists are scrambling to find ways to blunt the risk.